Read more

November 16, 2020
1 min read
Save

Top in cardiology: Highlights from AHA Scientific Sessions

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Four of the five top stories in cardiology last week were based on presentations from the virtual American Heart Association Scientific Sessions.

During one presentation, researchers reported data that showed omega-3 fatty acid and vitamin D3 supplementation did not increase nor decrease the risk for atrial fibrillation. Also during the meeting, the American Heart Association (AHA) issued a call to action to address systemic racism in the United States.

Omega 3
Source: Adobe Stock

Read these and more top stories in cardiology below:

No benefit of daily omega-3, vitamin D supplementation for AF prevention

Taking omega-3 fatty acids and vitamin D3 supplements did not increase nor decrease the risk for incident atrial fibrillation over 5 years, according to results of the VITAL Rhythm trial. Read more.

AHA issues call to action to address systemic racism in US

In an AHA presidential advisory, the association issued a call to action with steps to be taken to address structural racism as a driver of health disparities. Read more.

Iron supplementation for deficiency in acute HF lowers risk for future hospitalization

Supplementation in iron-deficient patients hospitalized with acute heart failure (HF) reduced subsequent HF hospitalization by approximately 26% compared with placebo, according to findings from the AFFIRM-AHF trial. Read more.

Omecamtiv mecarbil lowers CV death/HF events in HFrEF: GALACTIC-HF

Omecamtiv mecarbil (Amgen/Cytokinetics/Servier), a novel selective cardiac myosin activator, was associated with an 8% reduction in cardiovascular death or first HF events in patients with HF with reduced ejection fraction, according to results of the GALACTIC-HF trial. Read more.

High LDL elevates CV risk in older patients; primary prevention may be appropriate

High LDL in older patients may confer increased risk for atherosclerotic CVD and myocardial infarction, and therefore this population may benefit from targeted LDL-lowering therapies, according to two studies published in The Lancet. Read more.